Yahoo Finance report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
Why ACHC Stock slipped -1.13% Today — RQD Quant Desk Flash
Acadia Healthcare Company Inc. (ACHC) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ACHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Acadia Healthcare Company Inc. (NASDAQ: ACHC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $29.62 (-1.13% 1D, market cap $2.79B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, ACHC ranks #497 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ACHC compare to CLOV and CELC in the Health Care sector?
▼
Within the Health Care sector (Medical Specialities), ACHC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -24.8%. By comparison, CLOV (Clover Health Investments Corp. (Class A)) holds a D- grade (36/100 RQD, P/E N/A, ROIC -29.3%, cap $2.37B) and CELC (Celcuity Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $3.38B). Among the 5-stock peer group, VCYT leads on earnings multiple (63.2x) while VCYT leads on capital efficiency (4.6% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ACHC?
▼
Per ACHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001520697), Acadia Healthcare Company Inc. generated $3.31B in revenue (+5.0% YoY), -$1.10B in net income, and -$439.9M in free cash flow against $5.53B in total assets and $2.47B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±8% realized swing band)
FRED Regime × Technicals: 75% of 52W Range • RSI-14 at 50.9 (NEUTRAL RANGE)
Balance-sheet & 10-K footnote risk deducts 15 pts from forensic ceiling
⚔️ Adversarial Opposing Case: What Could Spark a ACHC Turnaround Squeeze
While ACHC currently carries a cautious 38/100 (D-) rating due to SEC 10-K Forensic Risk (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($29.13) and Max Pain ($31.10) forces dealer call-delta covering toward $37.62.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why ACHC Stock slipped -1.13% Today — RQD Quant Desk Flash
Acadia Healthcare Company Inc. (ACHC) slipped -1.13% to $29.62, trading at 75% of its 52-week range ($11.43 – $35.83). Stretched risk/reward at current multiples (-25% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 75% of its 52-week range ($11.43 – $35.83) with RSI-14 at 50.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8% around $29.62 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Yahoo Finance report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
EW heads into Q3 with TAVR momentum, expanding mitral and tricuspid therapies and surgical heart growth. Can it beat earnings estimates?
Ondas, Dutch Bros and Under Armour are among the most-heavily shorted stocks in the market right now.
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACHC)
- ✓Walkthrough of ACHC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
ACHC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +5.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ACHC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ACHC. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACHC)
1. Head-to-Head Health Care Peer Comparison (ACHC vs. CLOV, CELC, FTRE, VCYT)
Industry: Medical Specialities (41 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Acadia Healthcare Company Inc. (ACHC) ranks #497 by composite RQD confidence (38/100, grade D-) and #212 by equity capitalization ($2.79B). Within this direct 5-issuer industry benchmark cohort, VCYT leads on earnings valuation at 63.2x trailing P/E, while VCYT leads on capital efficiency and profitability with 4.6% ROIC and 70.1% gross margin. VCYT currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with ACHC at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ACHC
ACTIVE
Acadia Healthcare Company Inc. | D- | 38/100 | — | — | -24.8% | -1.13% | $2.79B | Benchmark Subject |
| CLOV Clover Health Investments Corp. (Class A) | D- | 36/100 | — | — | -29.3% | -3.36% | $2.37B | /clov-vs-achc → |
| CELC Celcuity Inc. | E | 31/100 | — | — | -35.0% | -2.98% | $3.38B | /celc-vs-achc → |
| FTRE Fortrea Holdings Inc. | E | 32/100 | — | — | -35.0% | -5.96% | $2.05B | /ftre-vs-achc → |
| VCYT Veracyte Inc. | B | 73/100 | 63.2x | 70.1% | 4.6% | -2.02% | $4.02B | /vcyt-vs-achc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001520697 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Acadia Healthcare Company Inc. (ACHC) reported GAAP revenue of $3.31B (+5.0% vs. FY2024 revenue of $3.15B , and +13.1% cumulative change since FY2023) , GAAP net income of -$1.10B, operating cash flow of $131.9M, and free cash flow of -$439.9M (+21.5% YoY). On the balance sheet, ACHC closed FY2025 with $5.53B in total assets against $2.47B in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.31B | -$1.10B | $131.9M | -$439.9M | $5.53B | $2.47B |
| FY2024 (FY) | 2024-12-31 | $3.15B | $255.6M | $129.7M | -$560.7M | $5.96B | $1.88B |
| FY2023 (FY) | 2023-12-31 | $2.93B | -$21.7M | $462.3M | $330.5M | $3.51B | $822.4M |
3. ACHC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ACHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Acadia Healthcare Company Inc. (NASDAQ: ACHC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $29.62 (-1.13% 1D, market cap $2.79B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, ACHC ranks #497 in composite RQD confidence.
How does ACHC compare to CLOV and CELC in the Health Care sector?
Within the Health Care sector (Medical Specialities), ACHC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -24.8%. By comparison, CLOV (Clover Health Investments Corp. (Class A)) holds a D- grade (36/100 RQD, P/E N/A, ROIC -29.3%, cap $2.37B) and CELC (Celcuity Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $3.38B). Among the 5-stock peer group, VCYT leads on earnings multiple (63.2x) while VCYT leads on capital efficiency (4.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ACHC?
Per ACHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001520697), Acadia Healthcare Company Inc. generated $3.31B in revenue (+5.0% YoY), -$1.10B in net income, and -$439.9M in free cash flow against $5.53B in total assets and $2.47B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ACHC trading relative to its 50-day, 200-day, and 52-week technical levels?
ACHC last traded at $29.62 (-1.13% on volume of 1,256,354 shares), positioning the stock +1.68% above its 50-day simple moving average ($29.13) and +13.70% above its 200-day simple moving average ($26.05). Across its 52-week range of $11.43 to $35.83, ACHC sits at the 74.5% percentile with a 14-day RSI of 50.9 (NEUTRAL RANGE) and an implied next-earnings move of ±8.0% ($27.25 to $31.99).
ACHC — Acadia Healthcare Company Inc.: What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
Acadia Healthcare Company Inc. (ACHC) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $29.62 (-1.13% 1D, market capitalization $2.79B).
- Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -24.8%, gross margin of —, operating margin of -40.6%, and free cash flow yield of -16.04%.
- Whale 13F & Options Flow (14/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (5/20): Incorporates a 1.07x equity beta, Altman Z-Score of 0.45, Piotroski F-Score of 5/9, and Debt/Equity of 1.27x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Acadia Healthcare Company Inc. Is a NASDAQ-listed issuer in the Health Care sector and the Medical Specialities industry. The profile does not describe its products, customers, or revenue model. The company reported revenue of $3.31B for FY 2025, indicating a substantial operating scale.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Acadia Healthcare Company Inc. (ACHC) reported $3.31B in annual revenue (up from $3.15B in FY2024, +5.0% YoY) and -$1.10B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.93B revenue, -$21.7M net income) through FY2025, ACHC scaled operating cash flow to $131.9M and free cash flow to -$439.9M, backed by $5.53B in total assets against $2.47B in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -16.04% and institutional whale pillar of 14/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $11.43 – $35.83 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -40.6% operating margins and a 1.07x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The only sector-level input is beta of 1.07 and the Health Care / Medical Specialities classification.
- Key Question #1: Can ACHC sustain or expand its -40.6% operating margin and -24.8% ROIC against Medical Specialities peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $3.31B and free cash flow of -$439.9M, how will capital allocation balance growth reinvestment against $2.47B in total debt?
- Key Question #3: How sensitive is ACHC's 21.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.07x)?
ACHC Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Acadia Healthcare Company Inc. (ACHC) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Acadia Healthcare Company Inc. (ACHC) market action, institutional positioning, and fundamental catalysts.
ACHC Bull vs. Bear Conversation Board — What's Your Call at $29.62?
Forward P/E of 21 against negative trailing EPS suggests the market is pricing in a recovery, and two news headlines frame the stock as
Forward P/E of 21 against negative trailing EPS suggests the market is pricing in a recovery, and two news headlines frame the stock as undervalued.. When you look under the hood at ACHC, Fundamental Cash Engine is 5/20 with 0.0% gross margins and -24.8% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (14/20) has been quietly accumulating below $35.83. My 12M target is $38.05.
@RedlineAuditor Fair point on 21.0x forward P/E, but you're ignoring the forward operating leverage in Medical Specialities. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
Altman Z of 0.45, Debt/Equity of 1.27, FCF yield of -16.04%, and ROIC of -24.8% place the balance sheet and cash engine in the weakest
Careful chasing ACHC at $29.96. Altman Z of 0.45, Debt/Equity of 1.27, FCF yield of -16.04%, and ROIC of -24.8% place the balance sheet and cash engine in the weakest tier of the RQD rating.. Gross margin is 0.0%, but operating margin is -40.6%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $23.07 on multiple compression.